Biomedicines 2013, 1(1), 1-2; doi:10.3390/biomedicines1010001
Editorial

Biomedicines—Moving Biologic Agents into Approved Treatment Options

email
Received: 8 March 2013; Accepted: 8 March 2013 / Published: 11 March 2013
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Note: In lieu of an abstract, this is an excerpt from the first page.

Excerpt: The development of biologic agents for therapeutic purposes, or biomedicines, has seen an active area of research both at the bench and in clinical trials. There is mounting evidence that biologic products can provide effective therapy for diseases that have been unresponsive to traditional pharmacologic approaches. Monoclonal antibody therapy for cancer and rheumatologic diseases has become a well accepted part of disease treatment plans. Gene therapy products have been approved in China and Europe. Bioengineering of new agents capitalizing on microRNA biology, nanoparticle technology, stem cell biology, and an increasing understanding of immunology predict a rich future for product development. [...]
PDF Full-text Download PDF Full-Text [96 KB, Updated Version, uploaded 14 March 2013 08:32 CET]
The original version is still available [96 KB, uploaded 11 March 2013 17:06 CET]

Export to BibTeX |
EndNote


MDPI and ACS Style

Cornetta, K. Biomedicines—Moving Biologic Agents into Approved Treatment Options. Biomedicines 2013, 1, 1-2.

AMA Style

Cornetta K. Biomedicines—Moving Biologic Agents into Approved Treatment Options. Biomedicines. 2013; 1(1):1-2.

Chicago/Turabian Style

Cornetta, Kenneth. 2013. "Biomedicines—Moving Biologic Agents into Approved Treatment Options." Biomedicines 1, no. 1: 1-2.

Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert